source
- Update: FDA investigates Novartis' Zolgensma following 9 cases of tumors in treated patientsAfter Novartis confirmed the reports of tumors in patients who have been treated with the spinal muscular atrophy gene therapy, the FDA will determine if any regulatory action is needed for Zolgens…BioSpace · 11d ago↗ source
- Recon: FDA orders new eye risk warnings for Ozempic, Zepbound; FDA launches investigation of Novartis’ Zolgensma after cancer ca...Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.raps · 12d ago↗ source
- Chinese biotech CEOs target creation of up to ten global Big Pharma firms within a decadeChinese drug developers have shifted from generic manufacturing to aiming for a seat at the global Big Pharma table, according to recent interviews. The country now ranks second after the United S…